Daré Bioscience (DARE) Q4 2024 earnings summary

Executive summary

• Announced plan to make proprietary sildenafil cream available via 503B compounding in 2025, accelerating access while pursuing FDA approval for female sexual arousal disorder.

• Expanded business strategy to include 503B compounding as a dual-path approach for select proprietary formulations.

• Zaciato, the first FDA-approved product, launched in the US in 2024 through a partnership with Organon.

• Progressed a diverse pipeline, including Ovaprene Phase III study, DARE HPV Phase II preparation, DARE-VVA1, DARE-PTB1, Casea S, and DARE-LARC1, with multiple clinical and regulatory milestones targeted for 2025.

Financial highlights

• General and administrative expenses for 2024 were $9.2 million, down 24% from 2023 due to reduced commercial readiness expenses and headcount.

• R&D expenses for 2024 were $14.2 million, a 34% decrease from 2023, primarily reflecting costs for Ovaprene's Phase 3 study.

• Year-end 2024 cash and equivalents were $15.7 million with a working capital deficit of $3.2 million.

• Reported total revenue of $9,784 for 2024, down from $2.8 million in 2023; net loss to common shareholders was $30.2 million, or $0.48 per share.

• Secured up to $20.7 million in non-dilutive funding from a federal agency and the Gates Foundation, and closed a $22 million royalty monetization transaction.

Outlook and guidance

• Targeting Q4 2025 for sildenafil cream availability via 503B partner; revenue and cash flow expected to begin in Q4 2025.

• Update on strategic partnerships and commercialization strategies expected in Q2 2025.

• Ovaprene Phase III interim DSMB safety review anticipated in summer 2025; full enrollment timeline uncertain due to federal funding disruptions.

• Plans to submit Phase 3 protocol for sildenafil cream to FDA in Q2 2025 and reach key Ovaprene study milestones by mid-2025.

• Advancing DARE HPV to Phase II and DARE VVA1 to Phase II, with additional programs in preclinical or early clinical stages.